Atropisomeric Racemization Kinetics of MRTX1719 Using Chiral Solvating Agent-Assisted 19F NMR Spectroscopy by Svitlana Kulyk, Susan M. De Paul, Matthew A. Marx, Torren M. Peakman, Christopher R. Smith

Get full text

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma by Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir, Christopher G. Wood

Get full text

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study by David Goldstein, Anna Spreafico, Ilan Weinreb, Trevor J. Pugh, Scott V Bratman, Bayardo Perez-Ordonez, Aaron R Hansen, Lillian Siu, Antony Tin, Alexey Aleshin, Amy Prawira, Jonathan Irish, John de Almeida, Douglas Chepeha, Stephen Smith, Marc Oliva, Daniel V Araujo, J. Javier Diaz-Mejia, Peter Olson, Tina Shek, Andrew Hope, Dax Torti, Jeffrey P. Bruce, Ben X. Wang, Anthony Fortuna, Hirak Der-Torossian, Ronald Shazer, Nickolas Attanasio, Qingyan Au, Jordan Feeney, Himanshu Sethi, Isan Chen

Get full text

Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway by Stephen J. Harwood, Christopher R. Smith, J. David Lawson, John M. Ketcham

Get full text

Peptides That Block RAS-p21 Protein-Induced Cell Transformation by Matthew R. Pincus, Bo Lin, Purvi Patel, Elmer Gabutan, Nitzan Zohar, Wilbur B. Bowne

“…Several new anti-oncogenic RAS-p21 agents, i.e., Amgen’s AMG510 and Mirati Therapeutics’ MRTX849, polycyclic aromatic compounds, have recently been FDA-approved and are already being used clinically to treat RAS-p21-induced NSCCL and colorectal carcinomas. …”
Get full text

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner by Pierre-Antoine Laurent, Marina Milic, Clément Quevrin, Lydia Meziani, Winchygn Liu, Daphné Morel, Nicolas Signolle, Céline Clémenson, Antonin Levy, Michele Mondini, Eric Deutsch

“…Among them, MRTX849 (Mirati Therapeutics) showed encouraging clinical outcomes for the treatment of selected patients with KRAS G12C mutated NSCLC and colorectal cancers. …”
Get full text